Search results for "FDG"

showing 4 items of 34 documents

Multiparametric 18F-FDG PET-MRI of the breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and …

2019

The rationale was to assess whether there are differences in multiparametric 18F-FDG PET/MRI biomarkers of contralateral healthy breast tissue in patients with benign and malignant breast tumors. Methods: In this institutional review board-approved prospective single-institution study, 141 women with imaging abnormalities on mammography or sonography (BI-RADS 4/5) underwent combined 18F-FDG PET/MRI of the breast at 3T with dynamic contrast-enhanced MRI, diffusion-weighted imaging, and the radiotracer 18F-FDG. In all patients, the following imaging biomarkers were recorded for the contralateral (tumor-free) breast: breast parenchymal uptake (BPU) (from 18F-FDG PET), mean apparent diffusion c…

medicine.medical_specialtyImaging biomarkerdiffusion-weighted imagingMalignancy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerF-18-FDG PET/MRImedicineMammographyEffective diffusion coefficientF-18-FDG PET/MRI breast cancer; dynamic contrast-enhanced MRI diffusion-weighted imaging imaging biomarkerimaging biomarkerRadiology Nuclear Medicine and imagingdynamic contrast-enhanced MRImedicine.diagnostic_testbusiness.industryCancermedicine.disease030220 oncology & carcinogenesisDynamic contrast-enhanced MRIRadiologybusinessDiffusion MRI
researchProduct

Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by 18F-FDG-PET/CT

2018

Objective:To investigate metabolic parameters as predictive of local response after stereotactic body radiation therapy (SBRT) for liver-oligometastases.Methods:Inclusion criteria of the present re...

medicine.medical_specialtyStereotactic body radiation therapybusiness.industryLiver NeoplasmsHumans; Liver Neoplasms; Retrospective Studies; Treatment Outcome; Fluorodeoxyglucose F18; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiosurgery; Radiology Nuclear Medicine and ImagingGeneral MedicineRadiosurgery030218 nuclear medicine & medical imaging03 medical and health sciencesTreatment Outcome0302 clinical medicineFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyNuclear Medicine and Imaging030220 oncology & carcinogenesisHumansMedicineRadiology Nuclear Medicine and imagingFdg pet ctRadiologyRadiopharmaceuticalsRadiologybusinessRetrospective StudiesThe British Journal of Radiology
researchProduct

Prognostic Value of Radiomics Signature By Diagnostic 18F-FDG PET/CT Analysis in Aggressive Non-Hodgkin's Lymphoma

2018

Abstract BACKGROUND Although the overall prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL) has improved, nearly a third of patients will have refractory disease or relapse. Identification of these high-risk patients using traditional prognostic factors is limited. PET is the recommended imaging modality for the staging of FDG-avid lymphoma but the value of a comprehensive new imaging biomarkers analysis applied to PET for the prediction of patients outcome has still not been deeply investigated. New metrics estimating the overall tumor burden such as metabolic tumor volume (MTV) and those that may capture intratumoral biological heterogeneity such as total lesion glycolysis…

medicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyMetabolic tumor volumemedicine.diseaseLinear discriminant analysisBiochemistryLymphomaNon-Hodgkin's lymphomaCorrelationRadiomicsKurtosisMedicineFdg pet ctRadiologybusinessBlood
researchProduct

Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT

2021

Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC), some patients show worsening disease during PSMA-RLT. We investigated the value of combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in this setting. In n = 29 mCRPC patients with worsening disease after a median of four cycles of [177Lu]Lu-PSMA-617 RLT, combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging was performed to detect [18F]FDG-avid lesions with low or no PSMA expression (mismatch lesions). To evaluate prognostic implication of mismatch, survival analyses regarding presence, location, and [18F]FDG PET-derived para…

radioligand therapy; PSMA; FDG; PET/CT; mismatch; metastatic castration-resistant prostate cancerCancer Researchmedicine.medical_specialtyFDGPET/CTUrology610Diseaseurologic and male genital diseasesMetastasisProstate cancerPSMAmedicineRC254-282Membrane antigenPET-CTbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensPet imagingMetabolic tumor volumemedicine.diseaseradioligand therapyTotal lesion glycolysismetastatic castration-resistant prostate cancerOncologybusinessmismatchCancers
researchProduct